For women who have not responded adequately to conventional therapy for severe IBS-D
When IBS-D symptoms disrupt her progress...Carve out another path.


For improved stool consistency, offer LOTRONEX
LOTRONEX is proven to reduce stool frequency1
Stools per day | ||
---|---|---|
Lotronex 1 mg BID (n=246) | Placebo(n=246) | |
Baseline | 3.2 | 3.2 |
Week 1 | 2.4* | 2.9 |
Week 6 | 2.2* | 2.8 |
Week 12 | 2.2* | 2.8 |
*P is less than 0.001.
From a retrospective analysis of 2 multicenter, double-blind, randomized, placebo-controlled studies in which a subgroup of 711 women with bowel urgency on ≥10 of 14 days during screening was identified.
References: 1. Data on file, Sebela Pharmaceuticals Inc. 2. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004;2:675-682.

For improved stool consistency, offer LOTRONEX
LOTRONEX is proven to improve stool consistency1,2
In a 12-week study measuring average stool consistency on a 5-point scale, patients improved from loose stools (4) at baseline to formed stools (3) at Week 12 with LOTRONEX (n=246) vs 3.5 with placebo (n=246). (P<0.001)
From a retrospective analysis of 2 multicenter, double-blind, randomized, placebo-controlled studies in which a subgroup of 711 women with bowel urgency on ≥10 of 14 days during screening was identified.
References: 1. Data on file, Sebela Pharmaceuticals Inc. 2. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004;2:675-682.